drugset / Trial / NCT00357682

A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia

NCT00357682

Phase 3 Completed 2557 enrolled University of Oxford AstraZeneca · collab
RandomizedFactorialOpen-labelPrevention

Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of esomeprazole and aspirin may prevent esophageal cancer in patients with Barrett's metaplasia. It is not yet known whether esomeprazole is more effective with or without aspirin in preventing esophageal cancer in patients with Barrett's metaplasia. PURPOSE: This randomized phase III trial is studying esomeprazole with or without aspirin to compare how well they work in preventing esophageal cancer in patients with Barrett's metaplasia.

Timeline

Start
2005-03-10
Primary completion
2017-05-31
Completion
2017-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 300 mg
Subject Esomeprazole Small molecule 20 mg
Subject Esomeprazole Small molecule 80 mg